20 August 2018 - - US-based pharmaceutical company Aeromics, Inc has appointed Mark Day, Ph.D. and Thomas Zindrick, J.D. to the Aeromics board of directors, the company said.

Mark Day, Ph.D. is a director and the president and chief executive officer at Bioasis Technologies Inc. (TSX.V: BTI) (OTCQB: BIOAF). Day also serves as adjunct associate professor at Yale University.

Day has more than 20 years of experience working in the industry.

He has developed business plans for Alexion Pharmaceuticals, Wyeth, Glaxo Smith Kline and Bristol-Myers Squibb in multiple functional areas ranging from the development of external research discovery engines and global scouting strategies to the creation of internal venture/investment funds.

He has established and managed more than 20 collaborations, mergers and acquisitions and licensing deals in research and development and business development.

Day was head of translational medicine neuroscience at Wyeth and was the co-chair of the early development team.

At Abbott, he was responsible for translational imaging and biomarkers across the R and D portfolios.

At BMS, Day was instrumental in the acquisition of iPierian and he has developed strategies that can shorten evaluation periods by several months, leading to early decisions regarding the advancement or early termination of the evaluative processes.

Day previously served as head, CNS virtual discovery, at Purdue Pharma. Prior to joining Purdue Pharma, he served as executive director, head of external research and scouting, at Alexion Pharmaceuticals, Inc.

He is recognised for his expertise and success in the recognition, evaluation and development of pipeline acquisition and collaboration targets across several therapeutic areas.

Day has presented his evaluations and formal recommendations at the highest corporate levels and has also participated in the resulting deal negotiations, leading to several high-profile acquisitions and collaborations.

Thomas Zindrick, J.D. is the president and chief executive officer of Genelux Corp., a clinical-stage biopharmaceutical company. He is a life sciences and biotechnology executive with a career spanning more than 25 years.

Zindrick joined Genelux Corp. in May 2014 after retiring from Amgen, Inc. where he built his 16-year career.

He has also served as chief executive officer of Amitech Therapeutic Solutions, Inc., a La Jolla, Calif.-based discovery and drug development company focused on commercializing allosteric kinase inhibitors.

During his career at Amgen, Zindrick held positions of increasing responsibility, including vice president, associate general counsel and chief compliance officer.

As vice president, associate general counsel, Zindrick led intellectual property, licensing and regulatory law teams, and served on cross-functional business and product development teams.

These teams were responsible for acquisitions totaling over USD 20bn and the licensing and development of six therapeutic products and numerous clinical candidates.

As chief compliance officer, he reported to the board of directors and led the corporate compliance program, which oversaw the compliance activities of numerous company functions including product development, manufacturing and marketing.

Prior to joining Amgen, Zindrick was an attorney at The Dow Chemical Company.

Zindrick earned his juris doctor degree from the University of Illinois College of Law and a bachelor of arts degree in biology from North Central College in Naperville, Ill.

Aeromics is a privately-held, clinical-stage pharmaceutical company developing a first-in-class anti-edema therapy to treat patients affected by acute central nervous system edema as a consequence of large hemispheric infarction.

The company was founded in 2006 by Marc F. Pelletier, M.Sc., Ph.D. and Walter F. Boron M.D., Ph.D., both Yale University scientists. Aeromics maintains headquarters in Branford, Conn. with offices in Cleveland, Ohio.